Deep brain stimulation (DBS) and Vagus nerve stimulation (VNS) devices treat a wide variety of disorders, most notably Parkinson’s disease and epilepsy. The 2021 combined prevalence of Parkinson’s disease and Epilepsy was approximately 5 million people within the US alone, with Parkinson’s accounting for 30% and Epilepsy accounting for the remaining 70%. In 2021, combined sales of DBS and VNS devices in the countries covered by this analysis totalled more than $1.2bn. Market drivers include the growing prevalence of Parkinson’s disease in certain regions due to the growing and ageing population, an ever-expanding list of indicated disorders, and increased technological innovation. Market limiters include supply chain disruptions, increased shipping costs, extensive exclusion criteria, and complicated implantation processes. This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the global markets for DBS & VNS devices. Countries covered by this report include the US, five major European markets (France, Germany, Italy, Spain, and the UK), and Japan. The forecast range for this report is 2021-26.
Table of Contents
Executive Summary
i. Combined market
ii. Methodology
Chapter 1: Clinical Overview
1.1 The nervous system
1.2 Deep brain stimulation
1.3 Vagus nerve stimulation
1.4 Movement disorders
1.5 Epilepsy
1.6 Major depressive disorder
1.7 Obsessive-compulsive disorder
1.8 Prevalence of neurological disorders
1.9 Bibliography
Chapter 2: Deep Brain Stimulation
2.1 Deep brain stimulation systems
2.2 Deep brain stimulation products
2.3 Developments in deep brain stimulation technology
2.4 Competing producers
2.5 Market forecast
2.6 Bibliography
Chapter 3: Vagus Nerve Stimulation
3.1 Vagus nerve stimulation systems
3.2 Vagus nerve stimulation products
3.3 Developments in vagus nerve stimulation technology
3.4 Competing producers
3.5 Market forecast
3.6 Bibliography
- Appendix A: Company List
